How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comPhase 2 Study of Terbium 161 PSMA in Lutetium-177 PSMA Naive mCRPC Patients
Description:
In this study it is aimed to analyze the efficacy and safety of Tb-161 PSMA I&T in the 7.4 GBq activity in a large patient group of Lu-177 PSMA naïve mCRPC patients. 3 cycles of Tb-161 PSMA will be administered with 6 weeks periods.
Sponsor:
Ankara University
Phase:
Phase 2
Contacts:
Cigdem Soydal (Professor)csoydal@yahoo.com
905333137701
Government Study Link:
NCT07441837 - Click here to see study onClinicalTrials.gov
Tb-161 PSMA I&T
Isotope(s):
TERBIUM-161
Radioisotope: Tb-161
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 6.9 Days
Decay Mode: BETA, GAMMA
Energy: Beta: Avg 154 keV Gamma: 49 keV (17%), 75 keV (10%)
Range: 0.5-30 micrometers
Decay Daughters: Dy161 (Stable)
Status: Clinical Trials Only
Target(s):
- PSMA
Ligand Class: Small Molecules
Chelator: DOTAGA
Share your feedback
Help us improve your experience